Published in Crit Rev Oncol Hematol on February 01, 2003
A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One (2013) 1.50
Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One (2011) 1.09
Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med (2008) 1.02
Alcohol consumption and the risk of nasopharyngeal carcinoma: a systematic review. Nutr Cancer (2009) 1.02
Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. Int J Clin Exp Med (2015) 0.81
Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay. Clin Epigenetics (2015) 0.79
Activation of multiple apoptotic pathways in human nasopharyngeal carcinoma cells by the prenylated isoflavone, osajin. PLoS One (2011) 0.78
Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion: 208 cases with a 10-year follow-up from a single institution. Oncol Lett (2012) 0.77
Integrin α9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma. Oncotarget (2015) 0.76
Old age at diagnosis increases risk of tumor progression in nasopharyngeal cancer. Oncotarget (2016) 0.75
MicroRNA-152 Targets Phosphatase and Tensin Homolog to Inhibit Apoptosis and Promote Cell Migration of Nasopharyngeal Carcinoma Cells. Med Sci Monit (2016) 0.75
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol (2017) 0.75
The incidence of Epstein-Barr virus in nasopharyngeal carcinoma of Jordanian patients. Eur Arch Otorhinolaryngol (2011) 0.75
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol (2007) 8.05
Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol (2008) 7.18
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst (2007) 4.14
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol (2003) 3.78
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 3.32
Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cancer. JAMA (2009) 3.27
False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis (2004) 3.06
Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87
Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med (2003) 2.76
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol (2009) 2.38
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant (2006) 2.37
Incidence of uveal melanoma in Europe. Ophthalmology (2007) 2.30
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol (2004) 2.29
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol (2012) 2.22
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol (2009) 2.18
Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther (2002) 2.13
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol (2011) 2.10
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst (2005) 2.09
Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC). J Epidemiol Community Health (2006) 2.06
Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation (2009) 1.85
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol (2013) 1.85
Major and minor salivary gland tumors. Crit Rev Oncol Hematol (2009) 1.77
Ovarian cancer. Crit Rev Oncol Hematol (2006) 1.64
Colon cancer. Crit Rev Oncol Hematol (2010) 1.62
Cholangiocarcinoma. Crit Rev Oncol Hematol (2008) 1.59
Glioblastoma in adults. Crit Rev Oncol Hematol (2008) 1.54
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol (2003) 1.47
Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer (2004) 1.42
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol (2006) 1.41
Ependymoma. Crit Rev Oncol Hematol (2007) 1.41
Cancer of the penis. Crit Rev Oncol Hematol (2005) 1.39
Preoperative concomitant hyperfractionated radiotherapy and gemcitabine for locally advanced rectal cancers: a phase I-II trial. Cancer J (2005) 1.38
Germ cell tumours of the testis. Crit Rev Oncol Hematol (2005) 1.37
Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer (2005) 1.37
Adult acute myeloid leukaemia. Crit Rev Oncol Hematol (2004) 1.37
Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer (2008) 1.35
Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol (2003) 1.33
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
The cure of cancer: a European perspective. Eur J Cancer (2009) 1.31
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol (2009) 1.27
Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori (2007) 1.27
Will Rogers phenomenon in multiple sclerosis. Ann Neurol (2008) 1.21
Comparative evaluation of autologous chondrocyte implantation and mosaicplasty: a multicentered randomized clinical trial. Clin J Sport Med (2005) 1.20
Cancer of the larynx. Crit Rev Oncol Hematol (2003) 1.19
Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study. Eur J Cancer (2006) 1.18
Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol (2004) 1.17
Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol (2007) 1.17
Gastric cancer. Crit Rev Oncol Hematol (2005) 1.16
The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori (2012) 1.15
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2006) 1.14
The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol (2005) 1.12
Survival in patients with uveal melanoma in Europe. Arch Ophthalmol (2008) 1.11
Three-dimensional conformal vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys (2004) 1.11
Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open (2013) 1.10
Cancer of the oropharynx. Crit Rev Oncol Hematol (2002) 1.09
Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol (2008) 1.08
Strategy for randomised clinical trials in rare cancers. BMJ (2003) 1.08
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer (2010) 1.08
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst (2011) 1.05
Comparative dosimetric evaluation of the simultaneous integrated boost with photon intensity modulation in head and neck cancer patients. Radiother Oncol (2003) 1.04
Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study. Int J Radiat Oncol Biol Phys (2005) 1.04
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol (2010) 1.03
Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol (2002) 1.03
Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol (2006) 1.03
Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol (2007) 1.03
Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys (2003) 1.03
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther (2011) 1.03
Retrospective study of childhood ganglioneuroma. J Clin Oncol (2008) 1.02
Oligodendroglioma. Crit Rev Oncol Hematol (2008) 1.01
Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther (2006) 1.01
Explaining gastric cancer survival differences among European countries. Int J Cancer (2004) 1.00
Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem (2003) 1.00
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol (2011) 1.00
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
Major and minor salivary glands tumours. Crit Rev Oncol Hematol (2003) 0.99
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood (2005) 0.99
Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer. Ann Thorac Surg (2004) 0.99
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol (2006) 0.99
Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol (2009) 0.99
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer (2006) 0.99
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res (2009) 0.99
Burn injury induces a change in T cell homeostasis affecting preferentially CD4+ T cells. J Leukoc Biol (2004) 0.99
Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treat Rev (2012) 0.97
An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health (2008) 0.97
A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J (2003) 0.96